Cancer surgery among patients older than 65 years is complex with high morbidity underscoring the need for specialized care at high-quality hospitals.

The most common adverse events reported in the neoadjuvant and adjuvant pembrolizumab plus enfortumab vedotin arm were pruritus, alopecia, diarrhea, fatigue and anemia. No new safety signals were ...

The TROP2 antibody drug conjugate (ADC) sacituzumab tirumotecan (sac-TMT) improved survival, compared with platinum-based chemotherapy, in patients with EGFR-mutated non-small cell lung cancer (NSCLC) ...

Of patients identified as low risk by combined clinicopathological factors and GEP test, only 7.1 percent were SLN-positive.

Researchers explored the effect of adding concurrent local therapy to tebentafusp in patients with metastatic uveal melanoma after progression.

This multivariate analysis also suggested the presence of previously unrecognized subclusters within the favorable prognosis category, indicating the potential for finer risk stratification.